WARREN, N.J., July 17, 2014 /PRNewswire/ -- Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $12.00 per share, before underwriting discounts. All of the common stock is being offered by Roka Bioscience. In addition, Roka Bioscience has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price. The shares are expected to begin trading on the NASDAQ Global Market on July 17, 2014 under the ticker symbol "ROKA". The offering is expected to close on July 22, 2014, subject to customary closing conditions.
BofA Merrill Lynch and Leerink Partners are acting as joint book-running managers for the offering. Cowen and Company and Wedbush PacGrow Life Sciences are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 16, 2014. When available, copies of the final prospectus relating to this offering may be obtained from BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, New York, NY 10038, or via email, at firstname.lastname@example.org; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, via email at email@example.com, or by phone at (800) 808-7525, ext. 4814.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.
Chief Financial Officer
|SOURCE Roka Bioscience, Inc.|
Copyright©2014 PR Newswire.
All rights reserved